Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $114.15 Consensus PT from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned a consensus rating of “Hold” from the twenty-two ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $113.45.

ZBH has been the topic of a number of research reports. JMP Securities dropped their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a report on Monday. Finally, Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th.

Zimmer Biomet Trading Up 3.1%

ZBH opened at $98.18 on Friday. The stock has a market capitalization of $19.42 billion, a PE ratio of 22.06, a P/E/G ratio of 1.95 and a beta of 0.78. The firm’s fifty day moving average price is $104.30 and its 200 day moving average price is $106.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet has a 12-month low of $89.92 and a 12-month high of $122.25.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.94 earnings per share. As a group, research analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.98%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s payout ratio is 21.24%.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.39% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently made changes to their positions in ZBH. Nordea Investment Management AB lifted its position in shares of Zimmer Biomet by 3.9% in the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 609 shares in the last quarter. ORG Partners LLC lifted its position in shares of Zimmer Biomet by 14,497.5% in the fourth quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock worth $617,000 after purchasing an additional 5,799 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Zimmer Biomet by 8.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock worth $1,710,000 after purchasing an additional 1,173 shares in the last quarter. Czech National Bank lifted its position in shares of Zimmer Biomet by 4.0% in the fourth quarter. Czech National Bank now owns 43,164 shares of the medical equipment provider’s stock worth $4,559,000 after purchasing an additional 1,678 shares in the last quarter. Finally, Brookstone Capital Management lifted its position in shares of Zimmer Biomet by 34.3% in the fourth quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider’s stock worth $906,000 after purchasing an additional 2,193 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.